Novocure stock soars 30% after FDA approves pancreatic cancer device

LootboxPhobia · 2026-02-12T02:50:37+00:00

Novocure's stock price surged over 30% after the FDA approved its Optune Pax device for the treatment of locally advanced pancreatic cancer. The device, combined with chemotherapy drugs, effectively disrupts cancer cell division and induces cell death. Studies show that the device delays pain progression, improves survival rates, and has a good safety profile.

LootboxPhobia

2026-02-12 02:50:37

Abstract generation in progress

Investing.com - Novocure (NASDAQ: NVCR) stock surged over 30% in after-hours trading on Wednesday after the U.S. Food and Drug Administration approved the company’s Optune Pax device for the treatment of locally advanced pancreatic cancer.

This wearable device, used in combination with the chemotherapy drug gemcitabine and albumin-bound paclitaxel, delivers tumor-treating electric fields (TTFields). These alternating electric fields are designed to disrupt cancer cell division and trigger cell death, while not significantly damaging healthy tissue.

Subscribe to InvestingPro for quick Wall Street updates

The company’s stock rose more than 30% to $13.80 before 8:19 a.m. Eastern Time (8:19 p.m. Beijing time), after initially climbing over 50% in after-hours trading.

The approval was based on results from the Phase 3 PANOVA-3 clinical trial, which enrolled 571 patients.

The study also showed that the device significantly delayed pain progression and improved one-year survival rates, with safety profiles comparable between the two treatment groups.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.